Results 281 to 290 of about 52,991 (293)
Some of the next articles are maybe not open access.
Apolipoprotein(a): A Puzzling Evolutionary Story
Journal of Molecular Evolution, 1997Human apolipoprotein(a), a risk factor for heart disease, has over 80% sequence identity to plasminogen. Plasminogen contains five distinct kringle domains plus a catalytic protease subunit. Human apo(a) consists of multiple copies (the number varies in individuals) of a domain resembling kringle 4, a single copy of a domain resembling kringle 5, and a
Lawn R +3 more
openaire +3 more sources
Nihon rinsho. Japanese journal of clinical medicine, 1995
Apo (a) consists of multiple tandem repeat of kringle 4, which resembles a counterpart of plasminogen. Plasma Lp (a) levels are genetically determined primarily by alleles at the apo (a) gene. Apo (a) shows size heterogeneity on the analysis of the protein and the mRNA.
openaire +1 more source
Apo (a) consists of multiple tandem repeat of kringle 4, which resembles a counterpart of plasminogen. Plasma Lp (a) levels are genetically determined primarily by alleles at the apo (a) gene. Apo (a) shows size heterogeneity on the analysis of the protein and the mRNA.
openaire +1 more source
Nihon rinsho. Japanese journal of clinical medicine, 1995
Apolipoproteins A include apoA-I, apoA-II and apoA-IV. These apolipoproteins are involved in the metabolism of HDL and reverse cholesterol transport. The genes encoding apoA-I, apoA-II and apoA-IV have arisen from a common ancestor. This review describes the structures of the genes encoding apoA-I, apoA-II and apoA-IV, and the structures and functions ...
openaire +1 more source
Apolipoproteins A include apoA-I, apoA-II and apoA-IV. These apolipoproteins are involved in the metabolism of HDL and reverse cholesterol transport. The genes encoding apoA-I, apoA-II and apoA-IV have arisen from a common ancestor. This review describes the structures of the genes encoding apoA-I, apoA-II and apoA-IV, and the structures and functions ...
openaire +1 more source
Apolipoprotein A-IMilano: current perspectives
Current Opinion in Lipidology, 2003Strategies to increase HDL are among the major targets of clinical research in atherosclerosis prevention. The mutant apolipoprotein A-I(Milano) has been associated with a reduced incidence of coronary disease in carriers. Furthermore, recombinant apolipoprotein A-I(Milano) has displayed remarkable atheroprotective activities and the possibility of ...
G. Chiesa, C.R. Sirtori
openaire +2 more sources
Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome
Current Opinion in Lipidology, 2007The goal of identifying subjects with metabolic syndrome is to detect those at higher risk of developing cardiovascular disease. Evidence continues to accumulate as to the superiority of apolipoprotein B and apolipoprotein A-I over the conventional lipoprotein lipids as markers of vascular risk.
Allan D, Sniderman, May, Faraj
openaire +2 more sources
Mutants of Apolipoproteins A and C
1986The determination of the circulating levels of apolipoproteins has become common practice in clinical laboratories, in view of the apparent correlation between levels of specific apolipoproteins and increased or decreased cardiovascular risk [1, 2].
C. R. Sirtori, M. R. Lovati
openaire +3 more sources
Pharmacology of apolipoprotein A-l
Current Opinion in Lipidology, 1997The role of HDL and its main protein component the apolipoprotein A-I as being antiatherogenic is well established. Experimental data give support for the involvement of at least three different types of mechanism: (1) the reverse cholesterol transport, (2) anti-inflammatory mechanisms and (3) antithrombotic mechanisms.
openaire +2 more sources
Alzheimer Disease, Apolipoprotein E, and Apolipoprotein(a)
Annals of Internal Medicine, 2000openaire +1 more source
[Lipid-poor apolipoprotein A-I, glycated apolipoprotein A-I].
Nihon rinsho. Japanese journal of clinical medicine, 2005Satoshi, Maeda +2 more
openaire +1 more source